Daphnetin

DB18965InvestigationalSmall molecule

Daphnetin is under investigation in clinical trial NCT06329167 (Daphnetin Capsules for Lower Limb Lymphoedema Following Gynaecological Surgery).

Mechanism: Pharmacologically active on Epidermal growth factor receptor, Protein kinase C, and cAMP-dependent protein kinase (Protein kinase A)
Curator reviewed
Formula / weight: C₉H₆O₄ · 178.143 g/mol (avg)
Also known as: 2h-1-benzopyran-2-one, 7,8-dihydroxy- · 7,8-dihydroxy-2h-1-benzopyran-2-one · 7,8-dihydroxycoumarin
Code names: NSC-633563

Resolves to

Compound

Clinical / RWD

Structure

InChIKeyATEFPOUAMCWAQS-UHFFFAOYSA-NSMILESOC1=CC=C2C=CC(=O)OC2=C1O

Targets

What you can answer from here — as of July 09, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Daphnetin, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.